Ranked 17th in the Indian pharmaceutical industry (source: Awacs March 2022).
Leader by Rx in Diabetes & Cardiology segments.
We are the leaders in the oral anti-diabetic segment in India in terms of both prescriptions and value. It is a position we have held consistently for almost two decades. Our anti-diabetes portfolio contributes to 47% to our Indian branded sales (March, 2021-2022).
We are also leaders in the cardiovascular disease segment in terms of prescription generation. In terms of value, we rank fourth. The cardiology portfolio contributes to 34% of our Indian branded sales (March, 2021-2022).
Presence in Nutritional and Gynaecology segments through innovative products from partners in USA and Europe and in Cosmetology with a leading European brand.
Website Development by Sharptech Digital Marketing Agency